Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Oncology

• Publication date

  2011-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2010.34.2980PMID 21709188PMCID PMC3157963
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Advances in Brief Loss of Heterozygosity in Familial Tumors from Three BRCAJ-linked Kindreds'

  2013cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer

  2009cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

  2008influential reference
• Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.

  2008influential reference
• Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.

  2008cited by this paper
• Resistance to therapy caused by intragenic deletion in BRCA2

  2008cited by this paper
• BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

  2005cited by this paper
• BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis

  2005cited by this paper
• Improved survival in women with BRCA‐associated ovarian carcinoma

  2003cited by this paper
• Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

  2002cited by this paper
• Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.

  2001cited by this paper
• BRCA2 is required for homology-directed repair of chromosomal breaks.

  2001cited by this paper
• The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin*

  2000cited by this paper
• Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.

  2000cited by this paper
• Brca1 controls homology-directed DNA repair.

  1999cited by this paper
• BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.

  1999cited by this paper
• An Overview of Cyclophosphamide and Ifosfamide Pharmacology

  1997cited by this paper
• Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13.

  1995cited by this paper
• Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13.

  1995cited by this paper
• Edinburgh Research Explorer Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma

  year unknowninfluential reference

• A Clinically Translatable Multimodal Deep Learning Model for HRD Detection from Histopathology Images

  2026cites this paper
• Novel therapeutic potential of the PARP inhibitor talazoparib in synovial sarcoma and its combined effect with ATR inhibitor

  2026cites this paper
• Deciphering brain metastasis in epithelial ovarian cancer: multimodal analysis and potential biomarkers

  2026cites this paper
• The Landscape of Personalized Medicine in Gynecologic Cancer.

  2025cites this paper
• Treatment of ovarian cancer: From the past to the new era (Review)

  2025cites this paper
• Revisiting Genomic Instability, Tumor Microenvironment and Immune Response in High-Grade Serous Ovarian Cancer

  2025cites this paper
• Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching.

  2025cites this paper
• Steroid‐Modulated Transcription Synergistically Forms DNA Double‐Strand Breaks With Topoisomerase II Inhibitor

  2025cites this paper
• SPHK1 enhances olaparib resistance in ovarian cancer through the NFκB/NRF2/ferroptosis pathway

  2025cites this paper
• Platinum-resistant ovarian cancer: From mechanisms to treatment strategies

  2025cites this paper
• FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models

  2025cites this paper
• Immunotherapy for Platinum-Resistant Ovarian Cancer as a Glimmer of Hope

  2025cites this paper
• Association between ancestry and tumor somatic mutations in a large national cohort of women with breast cancer

  2025cites this paper
• Isoform-specific function of NSD3 in DNA replication stress confers resistance to PARP inhibitors in prostate cancer.

  2025cites this paper
• Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase Inhibitors

  2025cites this paper
• Analytical validation of a homologous recombination deficiency signature (HRDsig) in pan-tumor tissue samples

  2025cites this paper
• Targeting DNA damage response pathways in tumor drug resistance: Mechanisms, clinical implications, and future directions.

  2025cites this paper
• Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors

  2025cites this paper
• Role of KLF5 in enhancing ovarian cancer stemness and PARPi resistance: mechanisms and therapeutic targeting

  2025cites this paper
• Expression of HECTD3 in Epithelial Ovarian Cancer and Its Effect on Platinum Resistance

  2025cites this paper
• Examining patient-specific responses to PARP inhibitors in a novel, human induced pluripotent stem cell-based model of breast cancer

  2025cites this paper
• Perspectives on cancer therapy—synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges

  2025cites this paper
• Integrating bulk RNA-seq and scRNA-seq analyses with machine learning to predict platinum response and prognosis in ovarian cancer

  2025cites this paper
• Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer.

  2025cites this paper
• Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistance

  2025cites this paper
• Recommendations for Clinical Molecular Laboratories for Detection of Homologous Recombination Deficiency in Cancer: A Joint Consensus Recommendation of the Association of Molecular Pathology, Association of Cancer Care Centers, and College of American Pathologists.

  2025cites this paper
• RAD51-mediated homologous recombination is a pro-tumour driver pathway

  2025cites this paper
• Targeting ovarian cancer using high-dose vitamin C therapy

  2025cites this paper
• Chemotherapy Induces an IL1β-dependent Neutrophil Recruitment that Promotes Chemoresistance in Metastatic Ovarian Cancer

  2025cites this paper
• BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality

  2024cites this paper
• Two-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in P-selectin–expressing cancers

  2024cites this paper
• UBA1 inhibition sensitizes cancer cells to PARP inhibitors

  2024cites this paper
• Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors

  2024cites this paper
• Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms

  2024cites this paper
• Unravelling the molecular basis of PARP inhibitor resistance in prostate cancer with homologous recombination repair deficiency.

  2024cites this paper
• A 15-Gene prognostic signature with TFAP2B functioning in Platinum Resistance of Ovarian Carcinoma

  2024cites this paper
• BRCA1 and BRCA2 Mutations in Carcinoma Ovary: A Prospective Cohort Study

  2024cites this paper
• Mathematical modeling framework enhances clinical trial design for maintenance treatment in oncology

  2024cites this paper
• Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient

  2024cites this paper
• Potential promising of synthetic lethality in cancer research and treatment

  2024cites this paper
• Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response

  2024cites this paper
• Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

  2024cites this paper
• BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges

  2024cites this paper
• Molecular Pathology of Ovarian Epithelial Neoplasms: Predictive, Prognostic, and Emerging Biomarkers.

  2024cites this paper
• Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.

  2024cites this paper
• UFL1 triggers replication fork degradation by MRE11 in BRCA1/2-deficient cells

  2024cites this paper
• Targeting the Cdc2‐like kinase 2 for overcoming platinum resistance in ovarian cancer

  2024cites this paper
• 5hmC enhances PARP trapping and restores PARP inhibitor sensitivity in chemoresistant BRCA1/2-deficient cells

  2024cites this paper
• Clinical relevance of circulating tumor DNA in ovarian cancer: current issues and future opportunities

  2024cites this paper
• Statistical Methods Applied to Gene Expression Data to Explore Cancer Features

  2024cites this paper
• Personalized Medicine for Metastatic Prostate Cancer: The Paradigm of PARP Inhibitors.

  2023cites this paper
• STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer

  2023cites this paper
• The expression and mutation of BRCA1/2 genes in ovarian cancer: a global systematic study

  2023influential citation
• Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors

  2023cites this paper
• The Sensitization of Triple-Negative Breast Cancers to Poly ADP Ribose Polymerase Inhibition Independent of BRCA1/2 Mutation Status by Chemically Modified microRNA-489

  2023cites this paper
• Concurrent RB1 loss and BRCA-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma

  2023cites this paper
• BRCA1/2 reversion mutations in a pan‐cancer cohort

  2023cites this paper
• MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study

  2023cites this paper
• Unleashing the Power of Synthetic Lethality: Augmenting Treatment Efficacy through Synergistic Integration with Chemotherapy Drugs

  2023cites this paper
• Origin of Residual Tumor Masses in BRCA1/2-Driven Ovarian Carcinomas Treated by Neoadjuvant Chemotherapy: Selection of Preexisting BRCA1/2-Proficient Tumor Cells but Not the Gain of Second ORF-Restoring Mutation

  2023cites this paper
• Poly(ADP-ribose) polymerase inhibitors in the treatment landscape of triple-negative breast cancer (TNBC)

  2023cites this paper
• Clinical and translational advances in ovarian cancer therapy

  2023cites this paper
• Mass Spectrometry–Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective

  2023cites this paper
• Ovarian cancer treatment strategies: focus on PARP inhibitors

  2023cites this paper
• The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma

  2023cites this paper
• Rich dynamics of a predator-prey system with state-dependent impulsive controls switching between two means

  2023cites this paper
• Olaparib-Resistant BRCA2MUT Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival

  2023cites this paper
• Triumphs and challenges in exploiting poly(ADP‐ribose) polymerase inhibition to combat triple‐negative breast cancer

  2023cites this paper
• Unveiling the epigenomic mechanisms of acquired platinum‐resistance in high‐grade serous ovarian cancer

  2023cites this paper
• Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer

  2023cites this paper
• A NOTCH1 Mutation Found in a Newly Established Ovarian Cancer Cell Line (FDOVL) Promotes Lymph Node Metastasis in Ovarian Cancer

  2023cites this paper
• Olaparib and advanced ovarian cancer: Summary of the past and looking into the future

  2023cites this paper
• Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches

  2023cites this paper
• PARP molecular functions and applications of PARP inhibitors in cancer treatment

  2023cites this paper
• Nanoengineered Gallium Ion Incorporated Formulation for Safe and Efficient Reversal of PARP Inhibition and Platinum Resistance in Ovarian Cancer

  2023cites this paper
• Unravelling the Role of PARP1 in Homeostasis and Tumorigenesis: Implications for Anti-Cancer Therapies and Overcoming Resistance

  2023cites this paper
• Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency

  2023cites this paper
• Complete Pathological Response to Platinum-Based Neoadjuvant Chemotherapy in BRCA2-Associated Locally Advanced Pancreatic Cancer: A Case Report and Literature Review

  2023influential citation
• RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

  2023cites this paper
• Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma

  2023cites this paper
• Combination Treatment Strategies to Overcome PARP Inhibitor Resistance

  2023cites this paper
• ‘Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research’

  2022cites this paper
• Epigenetic basis for PARP mutagenesis in glioblastoma: A review.

  2022cites this paper
• The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer

  2022cites this paper
• Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.

  2022cites this paper
• Handling of Germline Findings in Clinical Comprehensive Cancer Genomic Profiling.

  2022cites this paper
• The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022

  2022cites this paper
• State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report.

  2022cites this paper
• BRCA1 protects against its own fragility.

  2022cites this paper
• Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer

  2022cites this paper
• Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors

  2022cites this paper
• Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors

  2022influential citation
• The genomic landscape of recurrent ovarian high grade serous carcinoma: the BriTROC-1 study

  2022cites this paper
• A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer

  2022cites this paper
• BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside

  2022cites this paper
• KIAA1529 regulates RAD51 expression to confer PARP inhibitors resistance in ovarian cancer

  2022cites this paper
• The molecular landscape of pancreatic ductal adenocarcinoma.

  2022cites this paper
• Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance

  2022cites this paper
• Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors

  2022cites this paper
• Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development

  2022cites this paper